Previous close | 65.38 |
Open | 65.54 |
Bid | 62.22 x N/A |
Ask | 68.62 x N/A |
Day's range | 64.91 - 65.75 |
52-week range | 64.74 - 87.53 |
Volume | |
Avg. volume | 51,015 |
Market cap | 81.514B |
Beta (5Y monthly) | 0.35 |
PE ratio (TTM) | 15.04 |
EPS (TTM) | 4.35 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 3.00 (3.81%) |
Ex-dividend date | 14 Sept 2023 |
1y target est | N/A |
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript April 25, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and […]